The company received funding from the "Nanjing 321 Talent Plan"
Release time:
2018-05-24
On April 30, 2014, the company’s “phosphoramidite-based guanine nucleotide anti-hepatitis B drug JQ-301” project with independent property rights successfully passed the review and received funding from the 2013 Nanjing 321 Science and Technology Talent Program.
On April 30, 2014, the company’s “phosphoramidite-based guanine nucleotide anti-hepatitis B drug JQ-301” project with independent property rights successfully passed the review and received funding from the 2013 Nanjing 321 Science and Technology Talent Program.
Biomedicine is a strategic new industry in Nanjing. The incidence of hepatitis B in my country is relatively high, and about 10% are hepatitis B virus carriers. Currently, the main treatment drugs are foreign original drugs (such as: telbivudine, entecavir, lamivudine, etc. ), its treatment market has long been monopolized by large foreign companies, and patient treatment costs are high.
JQ-301 is a new structure phosphoramidate guanine analog anti-hepatitis B drug developed by our company, which acts on DNA polymerase. In the drug evaluation, the drug has shown the advantages of strong anti-hepatitis B virus effect, low drug resistance rate, low toxicity and convenient administration, and is expected to have good clinical use prospects.
Address: Nanjing Life Science and Technology Innovation Park, 568 Longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province
